Prognostic Significance of Peripheral Blood Monocyte Count Among a National Cohort of Veterans with Pulmonary Fibrosis.

Kaul B, Petersen LA, Collard HR, Richardson P, Zhang N, Whooley MA, Bhattacharya M. Prognostic Significance of Peripheral Blood Monocyte Count Among a National Cohort of Veterans with Pulmonary Fibrosis. Annals of the American Thoracic Society. 2026 Jan 1; 23(1):56-62, DOI: 10.1513/AnnalsATS.202410-1108OC.

Related HSR&D Project(s)

• CDA 23-137 – Improving Timely Access to Care for Veterans with Pulmonary Fibrosis Detected on Lung Cancer Screening

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

RATIONALE: Elevated peripheral blood monocyte counts (PBMCs) are associated with disease progression and mortality in patients with idiopathic pulmonary fibrosis (IPF). However, evidence for progression stems primarily from highly curated cohort studies or post hoc analysis of clinical trials. OBJECTIVES: We used real-world data to examine the association between PBMC and IPF mortality among a national cohort of Veterans with IPF. METHODS: We used an International Classification of Disease code-based electronic health record algorithm to identify Veterans with IPF. Those who had a PBMC available within 180 days of index IPF diagnosis were included in the analytical cohort. Mortality analyses were conducted using Cox proportional hazard models. RESULTS: We identified 30,419 Veterans with IPF and a PBMC available for analysis. Veterans with PBMC???0.95?×?109 cells/L had a 51% higher risk of all-cause mortality (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.44-1.58; P? < 0.001) in an unadjusted analysis. The risk persisted in models adjusted for age and sex (HR, 1.43; 95% CI, 1.36-1.50; P? < 0.001) and after adjustment for oxygen use as a surrogate marker of disease severity (HR, 1.35; 95% CI, 1.29-1.41; P? < 0.001). There was a stepwise increase in mortality risk as PBMCs increased, with a monocyte dichotomization threshold between 0.4 and 0.5?×?109 cells/L associated with HR for mortality of greater than 1.0 for both unadjusted and adjusted models. CONCLUSIONS: We found that a stepwise increase in PBMC was associated with an increased all-cause IPF mortality. A PBMC dichotomization threshold between 0.4 and 0.5?×?109 cells/L, which is lower than previously reported, was associated with an increased risk of mortality.